Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.

Authors

S Rule
W Jurczak
M Jerkeman
C Rusconi
et al

DOI

10.1038/s41375-018-0023-2

Publication Date

2018-02-02

Publication Title

Leukemia

Publisher

Springer Science and Business Media LLC

ISSN

1476-5551

Embargo Period

2024-11-19

Additional Links

https://www.ncbi.nlm.nih.gov/pubmed/29572505

Recommended Citation

Rule, S., Jurczak, W., Jerkeman, M., Rusconi, C., & et al. (2018) 'Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.', Leukemia, . Springer Science and Business Media LLC: Available at: https://doi.org/10.1038/s41375-018-0023-2